← Previous revision | Revision as of 07:40, 8 May 2024 |
| Line 25: | Line 25: |
| Celera sequenced the human genome at a fraction of the cost of the publicly funded [[Human Genome Project]] (HGP), using about $300 million of private funding versus approximately $3 billion of taxpayer dollars.{{cn|date=December 2022}} However, a significant portion of the human genome had already been sequenced when Celera entered the field, and thus Celera did not incur any costs with obtaining the existing data, which was freely available to the public from [[GenBank]]. Celera's approach, which used [[shotgun sequencing]], spurred the public HGP to accelerate its effort and shift its projected timetable from 2005 to 2003.{{Citation needed|date=January 2020}} | Celera sequenced the human genome at a fraction of the cost of the publicly funded [[Human Genome Project]] (HGP), using about $300 million of private funding versus approximately $3 billion of taxpayer dollars.{{cn|date=December 2022}} However, a significant portion of the human genome had already been sequenced when Celera entered the field, and thus Celera did not incur any costs with obtaining the existing data, which was freely available to the public from [[GenBank]]. Celera's approach, which used [[shotgun sequencing]], spurred the public HGP to accelerate its effort and shift its projected timetable from 2005 to 2003.{{Citation needed|date=January 2020}} |
| Critics of initial efforts by Celera Genomics to hold back data from sections of genome they sequenced for commercial exploitation felt that it would retard progress in science as a whole. These critics pointed to the [[Open access (publishing)|open access]] policy for gene sequences from the publicly funded Human Genome Project. Later, the company changed their policy and made their sequences available for non-commercial use but set a maximum threshold for amount of sequence data that a researcher could download at any given time.{{Citation needed|date=January 2020}} | Critics of initial efforts by Celera Genomics to hold back data from sections of genome they sequenced for commercial exploitation felt that it would retard progress in science as a whole. These critics pointed to the [[Open access (publishing)|open access]] policy for gene sequences from the publicly funded Human Genome Project<ref>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1119622/ Dispute as rival groups publish details of human genome, Feb 17, 2001.</ref>. Later, the company changed their policy and made their sequences available for non-commercial use but set a maximum threshold for amount of sequence data that a researcher could download at any given time.{{Citation needed|date=January 2020}} |
| The rise and fall of Celera as an ambitious competitor of the Human Genome Project is the main subject of the book ''The Genome War'' by James Shreeve, who followed Venter around for two years in the process of writing the book. A view from the public effort's side is that of [[Nobel laureate]] Sir [[John Sulston]] in his book ''The Common Thread: A Story of Science, Politics, Ethics and the Human Genome''. Anthropologist Paul Rabinow also based his 2005 book ''A Machine to Make a Future'' on Celera. | The rise and fall of Celera as an ambitious competitor of the Human Genome Project is the main subject of the book ''The Genome War'' by James Shreeve, who followed Venter around for two years in the process of writing the book. A view from the public effort's side is that of [[Nobel laureate]] Sir [[John Sulston]] in his book ''The Common Thread: A Story of Science, Politics, Ethics and the Human Genome''. Anthropologist Paul Rabinow also based his 2005 book ''A Machine to Make a Future'' on Celera. |
Okumaya devam et...